Literature DB >> 2217661

Motor/vocal tics and compulsive behaviors on stimulant drugs: is there a common vulnerability?

B G Borcherding1, C S Keysor, J L Rapoport, J Elia, J Amass.   

Abstract

The occurrence of abnormal movements or perserverative/compulsive behaviors was noted in 34 (76%) of a group of 45 hyperactive boys during a double-blind crossover treatment trial of methylphenidate and dextroamphetamine given in a wide range of doses. These adverse effects were often subtle and transient, and they usually occurred only on one drug. There was only one case where treatment was discontinued due to the severity of the tic the subject developed during his initial treatment phase. Dextroamphetamine tended to produce more compulsive behaviors, which were also more likely to resemble clinical obsessive-compulsive disorder (OCD), than did methylphenidate. Abnormal movements and compulsive behaviors tended to co-occur on methylphenidate only; no general "Tourette-OCD diathesis" was found for this population.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2217661     DOI: 10.1016/0165-1781(90)90151-t

Source DB:  PubMed          Journal:  Psychiatry Res        ISSN: 0165-1781            Impact factor:   3.222


  16 in total

Review 1.  Rodent models of obsessive compulsive disorder: Evaluating validity to interpret emerging neurobiology.

Authors:  Isaac Zike; Tim Xu; Natalie Hong; Jeremy Veenstra-VanderWeele
Journal:  Neuroscience       Date:  2016-09-16       Impact factor: 3.590

Review 2.  Methylphenidate and its isomers: their role in the treatment of attention-deficit hyperactivity disorder using a transdermal delivery system.

Authors:  David J Heal; David M Pierce
Journal:  CNS Drugs       Date:  2006       Impact factor: 5.749

Review 3.  Drug-induced movement disorders.

Authors:  F J Jiménez-Jiménez; P J García-Ruiz; J A Molina
Journal:  Drug Saf       Date:  1997-03       Impact factor: 5.606

4.  European clinical guidelines for hyperkinetic disorder -- first upgrade.

Authors:  Eric Taylor; Manfred Döpfner; Joseph Sergeant; Philip Asherson; Tobias Banaschewski; Jan Buitelaar; David Coghill; Marina Danckaerts; Aribert Rothenberger; Edmund Sonuga-Barke; Hans-Christoph Steinhausen; Alessandro Zuddas
Journal:  Eur Child Adolesc Psychiatry       Date:  2004       Impact factor: 4.785

Review 5.  Drug treatment for hyperactive children. Therapeutic guidelines.

Authors:  J Elia
Journal:  Drugs       Date:  1993-11       Impact factor: 9.546

Review 6.  Adverse effects of pharmacotherapies for attention-deficit hyperactivity disorder: epidemiology, prevention and management.

Authors:  Johnny Graham; David Coghill
Journal:  CNS Drugs       Date:  2008       Impact factor: 5.749

Review 7.  Drug and non-drug treatments of children with ADHD and tic disorders.

Authors:  Yann Poncin; Denis G Sukhodolsky; Joseph McGuire; Lawrence Scahill
Journal:  Eur Child Adolesc Psychiatry       Date:  2007-06       Impact factor: 4.785

Review 8.  Attention deficit hyperactivity disorder, tics and Tourette's syndrome: the relationship and treatment implications. A commentary.

Authors:  Mary M Robertson
Journal:  Eur Child Adolesc Psychiatry       Date:  2006-02       Impact factor: 4.785

Review 9.  Contemporary assessment and pharmacotherapy of Tourette syndrome.

Authors:  Lawrence Scahill; Gerald Erenberg; Cheston M Berlin; Cathy Budman; Barbara J Coffey; Joseph Jankovic; Louise Kiessling; Robert A King; Roger Kurlan; Anthony Lang; Jonathan Mink; Tanya Murphy; Samual Zinner; John Walkup
Journal:  NeuroRx       Date:  2006-04

Review 10.  Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD).

Authors:  Ole Jakob Storebø; Erica Ramstad; Helle B Krogh; Trine Danvad Nilausen; Maria Skoog; Mathilde Holmskov; Susanne Rosendal; Camilla Groth; Frederik L Magnusson; Carlos R Moreira-Maia; Donna Gillies; Kirsten Buch Rasmussen; Dorothy Gauci; Morris Zwi; Richard Kirubakaran; Bente Forsbøl; Erik Simonsen; Christian Gluud
Journal:  Cochrane Database Syst Rev       Date:  2015-11-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.